Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Analysis of IDH1 and IDH2 mutations in Japanese glioma patients.

Authors: Sonoda, Y  Kumabe, T  Nakamura, T  Saito, R  Kanamori, M  Yamashita, Y  Suzuki, H  Tominaga, T 
Citation: Sonoda Y, etal., Cancer Sci. 2009 Oct;100(10):1996-8. doi: 10.1111/j.1349-7006.2009.01270.x.
Pubmed: (View Article at PubMed) PMID:19765000
DOI: Full-text: DOI:10.1111/j.1349-7006.2009.01270.x

A recent study reported on mutations in the active site of the isocitrate dehydrogenase 1 (IDH1) gene in several types of gliomas. All mutations detected resulted in an amino acid exchange at position 132. We analyzed the genomic region spanning wild-type R132 of IDH1 by direct sequencing in 125 glial tumors. A total of 39 IDH1 mutations were observed. Mutations of the IDH2 gene, homologous to IDH1, were often detected in gliomas without IDH1 mutations. In the present study, R172 mutation of the IDH2 gene was detected in one anaplastic astrocytoma. IDH1 or IDH2 mutations were frequently in oligodendrogliomas (67%), anaplastic astrocytomas (62%), anaplastic oligoastrocytomas (75%), anaplastic oligodendrogliomas (50%), secondary glioblastomas (67%), gangliogliomas (38%), and anaplastic gangliogliomas (60%). Primary glioblastomas were characterized by a low frequency of mutations (5%) at amino acid position 132 of IDH1. Mutations of the IDH1 or IDH2 genes were significantly associated with improved outcome in patients with anaplastic astrocytomas. Our data suggest that IDH1 or IDH2 mutation plays a role in early tumor progression of several types of glioma and might arise from a common glial precursor. The infrequency of IDH1 mutation in primary glioblastomas revealed that these subtypes are genetically distinct entities from other glial tumors.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11522732
Created: 2016-08-05
Species: All species
Last Modified: 2016-08-05
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.